RecruitingPhase 1NCT04260022
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ascentage Pharma Group Inc.
- Principal Investigator
- Yifan Zhai, MD, PhDAscentage Pharma Group Inc.
- Intervention
- Ascentage Pharma HQP1351 bioavailable inhibitor(drug)
- Enrollment
- 242 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2030
Study locations (9)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- City of Hope, Duarte, California, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Augusta Cancer Center, Augusta, Georgia, United States
- University of Maryland, Baltimore, Maryland, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04260022 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn